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Abstract: Smallpox is an acute disease caused by infection with variola virus that has had 
historic effects on the human population due to its virulence and infectivity. Because 
variola remains a threat to humans, the discovery and development of novel pox 
therapeutics and vaccines has been an area of intense focus. As variola is a uniquely human 
virus lacking a robust animal model, the development of rational therapeutic or vaccine 
approaches for variola requires the use of model systems that reflect the clinical aspects of 
human infection. Many laboratory animal models of poxviral disease have been developed 
over the years to study host response and to evaluate new therapeutics and vaccines for the 
treatment or prevention of human smallpox. Rabbitpox (rabbitpox virus infection in 
rabbits) is a severe and often lethal infection that has been identified as an ideal disease 
model for the study of poxviruses in a non-rodent species. The aerosol infection model 
(aerosolized rabbitpox infection) embodies many of the desired aspects of the disease 
syndrome that involves the respiratory system and thus may serve as an appropriate model 
for evaluation of antivirals under development for the therapeutic treatment of human 
smallpox. In this review we summarize the aerosol model of rabbitpox, discuss the 
development efforts that have thus far used this model for antiviral testing, and comment 
on the prospects for its use in future evaluations requiring a poxviral model with a focus on 
respiratory infection.  
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1. Introduction 
The Poxviridae are members of a family of complex DNA viruses that replicate entirely in the 
cytoplasm of vertebrate or invertebrate cells. Two members of the family, variola virus (VARV) and 
molluscum contagiosum virus (MOCV) are obligate human pathogens, but others can be transmitted 
from animals to humans as zoonoses. VARV is the etiologic agent of human smallpox, a virus with 
historic impact on human health and continued potential as a biological weapon. Naturally occurring 
human smallpox was eradicated in 1977 after a coordinated global vaccination program. 
Corresponding prevention efforts, including mass vaccination campaigns of the general population 
were soon thereafter halted, leaving a new generation immunologically naïve and unprotected from 
viral infection. Nearly three decades later, serious concerns about the possibility of VARV being 
revived as a biological weapon were rekindled as a by-product of the worst act of bioterrorism in the 
history of the United States [1]. The subsequent risk assessment of approved medical products revealed 
how woefully unprepared we were to effectively protect and treat potential victims of a bioterrorist 
release involving VARV. This initiated a renewed interest in bolstering existing vaccine stocks as well 
as identification and evaluation of effective antivirals that demonstrate potency against poxviruses. In 
the absence of an animal reservoir, VARV now is maintained in two secured laboratory locations in 
the U.S. and Russia. Because of the increasing threat potential presented by terrorist or other 
organizations with intent to use biological weapons of mass destruction, development of 
countermeasures for VARV remain a priority for the U.S. government. The approach to VARV 
countermeasures includes vaccination of high risk of exposure individuals, and a post-exposure 
vaccine, immune globulin, or antiviral therapy for laboratory accidents or in the event of an 
intentionally produced exposure.  
Testing and evaluation of antiviral therapeutics effective against smallpox presents a number of 
logistical and scientific challenges, including limited access to VARV and lack of a clinical population 
to better understand disease pathogenesis in the natural host (man). One of the more troublesome 
problems in the research and development of effective antiviral therapeutics for smallpox is the lack of 
a disease model that emulates the human condition and can be referenced as a benchmark standard 
from which other animal models are measured. Specifically, there have been few identified poxviral 
animal models which incorporates salient aspects of human smallpox in terms of modality of exposure, 
clinical development and pathogenesis of disease. Rabbitpox virus (RPXV) and specifically rabbitpox 
(RPX) represents one such model that shares many similarities with smallpox; the most notable 
characteristic being significant involvement of the respiratory system when aerosol is used as the 
modality of experimental infection.  
2. Rabbitpox in Rabbits 
Rabbitpox virus (RPXV), a 56 kDa double stranded DNA virus within the family poxviridae, is the 
causative agent of rabbitpox disease (RPX) in rabbits. RPX first emerged and was reported from an 
outbreak in rabbits in Utrecht, Netherlands [2], and later in a second outbreak at Rockefeller Institute 
for Medical Research in the 1930s [3,4]; the former isolate subsequently is the progenitor of the viral 
strain commonly used for infection studies (Table 1) and genomic sequencing [5]. In both reports of Viruses 2010, 2                  
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the outbreak among the rabbit colonies, it was noted that the virus quickly spread throughout the 
animal population, apparently through both contact housing and through aerosol transmission, 
producing disease in a vast majority of the animals [3]. Animals involved in these outbreaks were 
described as showing a range of signs indicative of a disease that is now recognized as RPX infection. 
Subsequent studies using RPXV in rabbits have shown that experimental viral infection can induce a 
similar disease observed in early reports using a variety of routes of exposure [6–11], with some routes 
of exposure such as intradermal (ID) inoculation being preferred by some for the study of early stage 
poxviral pathogenesis [12–15]. The original outbreak of RPX was described as rabbits in both a 
contact and noncontact housing configuration; from these descriptions, it can be presumed that RPXV 
was aerosol-transmitted from infected host to a naïve cohort within the colony. The fact that RPXV 
was an aerosol-transmitted disease in a laboratory outbreak suggests that the virus and the resulting 
disease (RPX) is similar to VARV in that its natural route of transmission is through the infected 
respiratory secretions of the selected host.  
Airborne rabbit-to-rabbit RPX communicability of noncontact ID-inoculated and naïve animals has 
recently been described [14]. These cleverly-designed experiments demonstrate that RPX is in fact 
transmissible as an airborne virus when expelled via infectious aerosols or droplets by an infected host. 
This may be the underlying reason that early model development efforts incorporated aerosol as a 
preferred route of exposure for experimental infection [9–11]. The aerosol RPX model, the subject of 
this review, has the capacity to produce a disease that severely affects animals and when given at the 
appropriate dose, a lethal viral disease model.  
2.1. Experimental Aerosol Infection  
The signs and clinical development of the RPXV disease model have been detailed in a number of 
past reports [9,10]. The respiratory route of exposure to induce disease, or an experimental ‘aerosol’ 
model, was used extensively in the 1960s, and has recently been used in pathogenicity [16],   
antiviral [17], and vaccine efficacy studies [18]. Experimental infection with RPXV initiates with 
exposure to aerosols with a particle size distribution that is preferential for penetration to the 
tracheobronchial and pulmonary regions of the lung, with emphasis on the lower respiratory tract. 
Prior efforts have used particle size distributions with median diameters measuring at or under 1.0 
m[9]; recent studies also have used particle distributions similar to this size range [16–19]. It should 
be noted that the particle size distribution associated with normal expiration of rabbits (naïve or 
RPXV-infected) should be considered altogether different than the size distribution of aerosols used in 
experimental infection [20] (Figure 1).  
Deposition studies using radiolabeled particles with a similar size distributions as used in 
experimental infection estimates 50–80% of an inhaled dose will penetrate to the mid to lower lung of 
a rabbit [21]. In contrast, the particles contained in exhaled breath of rabbits are generally more 
heterogeneous and will shift initial deposition of infectious aerosols in the respiratory system to the 
mid and upper airways (Figure 1). Experimental infection with RPXV includes artificial generation of 
a viral suspension using a nebulizer into either nose-only or muzzle-only inhalation exposure system. 
This type of inhalation exposure has been performed using unanesthetized rabbits in an unrestrained 
breathing configuration during acute experimental procedure. Reporting of delivered inhaled dose of Viruses 2010, 2                  
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RPXV can be variable based upon selected method of sampling the aerosol during experimental 
infection and post hoc analysis of the collected aerosol sample. Reproducibility of the aerosol infection 
may be technically difficult to transfer to another laboratory attempting to recapitulate the model 
because of the equipment and biocontainment facilities required to perform this type of exposure. 
Reported doses of inhaled RPXV in prior studies using the aerosol model to cause near complete 
lethality has been >50 PFU, although the variability surrounding this dose estimate is potentially   
large [9,17]. The variability of dosage estimates based on the type of sampling performed during 
exposure, inhalation aerosol system in use, and other nuances about the experimental configuration, 
can make it exceedingly difficult to directly compare the infectious dose across studies (Table 1).  
Figure 1. Comparative particle size distributions
1 from aerosol generator used in 
experimental RPX infection and comparative particle counts of exhaled breath aerosols of 
a naïve NZW rabbit (inset graph).  
 
1 Ordinate axis represents the mass of particles between Dp and dlogDp (Dp = particle diameter). For 
the particle distribution generated by the nebulizer used in the experimental RPX infection, the 
transecting line for the distribution represents the mass median aerodynamic diameter (MMAD) 
and geometric standard deviation (g), respectively. The abscissa axis represents particle size in 
m. The particle distributions of the animal’s exhaled breath represent cumulative particle (count) 
for each discrete size selective bin.   
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Table 1. Reported RPXV aerosol doses and survival outcome. 
PRXV/strain  RPXV dose (PFU/animal) (reported) Group survival (%)  Reference
Utrecht/ 175  0/8  (0)  [7] 
Utrecht/Rockefeller 
15 
50 
250 
1/7 (14) 
1/8 (12) 
1/9 (11) 
[9] 
Utrecht 
 
2,860 
(1,140–5,000) 
0/6 (0)  [19] 
Utrecht 
 
296 
(96–468) 
0/6 (0)  [19] 
 
2.2. Aerosol RPX Model  
Following initial RPXV aerosol infection, a viral incubation lasting from two to three days ensues, 
similar to the timing of RPXV induced by other modalities of exposure such as intradermal (ID) 
inoculation [14]. High titers of RPXV developed in the respiratory system have shown to develop early 
(+24–36 h postexposure) in the aerosol infection model. Although temporal viral loading in the lungs 
of ID-innoculated animals has not been fully quanitated [14], significant respiratory involvement has 
been described as worsening at day 8–9 postinfection [17,22]. Notably, early viral dissemination into 
the ovaries and testicles has also been observed in past studies using aerosol infection [17]. The first 
signs of clinical disease manifesting as weight loss and hyperthermia begin to emerge on day 2–3 
postexposure and continue to worsen throughout the remainder of the illness. Other noted clinical signs 
of RPX infection that become evident at day 2–3 postexposure include anorexia, depression, facial and 
cervical edema, dehydration, and diarrhea. Significant mucus membrane involvement including thick 
serous discharge from the eyes and nose also accompanies other clinical signs of RPX infection.  
A characteristic feature of RPX disease that is similar to other poxviral infections is appearance of 
exthanema, and it has been the practice to shave the rabbit’s flank prior to exposure to observe 
development with any accuracy. The rash first appears in aerosol-infected animals as small papular 
lesions on day 4–5 postinfection, emerging mainly on the animal’s trunk. The rash continues to 
develop to vesicular lesions throughout the course of the illness, although death will often precede 
resolution of the rash due to the rapidly worsening clinical signs [22]. Most clinical signs associated 
with the aerosol model of RPX is similar to what is observed using ID inoculation model [14] with the 
exception of timing and development of the characteristic rash. In the ID model, the initial injection 
site shows infection and eventually becomes necrotic, with the appearance of secondary dermal lesions 
day 5–7 postexposure [14]. In the aerosol model, macular lesions are observed day 5–6 postexposure 
with distribution predominantly on the animal’s trunk [17].  
Respiratory involvement is also pronounced in the aerosol RPX model, and the severity of effect 
has been noted in recent reports using this exposure modality [17]. Rabbits infected by aerosol 
experience an acute onset (+3 days PI) of respiratory signs including hyperventilation and dyspnea, 
with a rapid worsening to frank respiratory distress and open-mouth breathing by day 6–7 PI. Aerosol 
infected rabbits have been observed to progress quicker to profound respiratory distress than infection 
via ID inoculation. The rapidity of respiratory involvement in aerosol-infected rabbits is likely Viruses 2010, 2                  
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associated with the direct targeting of the lung during the initial exposure. The particle size distribution 
that has been used in experimental aerosol RPXV infection specifically impacts the lower (pulmonary) 
region of the lung which is considered the most susceptible region of the respiratory system. The 
respiratory pathology that ensues after aerosol inoculation shows dramatic lung involvement   
(Figure 2), with almost complete lung involvement at the time of death (Day 6–7 PI).  
Figure 2. Two examples of lungs from naïve rabbits exposed to aerosolized RPXV taken 
at day +6 PI. The lungs are enlarged and heavy with patches of congestion, hemorrhage 
(arrows) and edema. Discoloration of the lung tissue defines collapsed areas of   
virally-induced inflammation bordered by light-colored aerated lobules. 
 
 
Histologically, evidence of edema, hemorrhage, and necrosis throughout the parenchyma of the 
lung indicative of an acute viral infection is evident (Figure 3). The respiratory pathology associated 
with aerosol infection emphasizes the severity of disease in this model for testing antiviral agents.  
3. Antivirals Used in Conjunction with Aerosol RPX Virus Infection Model 
A litany of antiviral compounds have been tested using a number of the orthopox viruses and the 
relevant corresponding disease models which have been thoroughly reported and reviewed in the 
literature [23–29] and are detailed in other articles included in this special issue of Viruses. There are 
few antiviral compounds, however, that have been assessed using the aerosol RPX model, a fact that 
has been highlighted in comprehensive reviews of antiviral screening in a number of animal   
models [27]. The limited use of this particular model in the evaluation of antiviral therapeutics may 
have to do with practical issues rather than the biological nuances of the model itself. The RPX aerosol 
model uses an animal species that requires significantly more housing space than rodents and requires the 
use of sophisticated inhalation equipment in specialized biocontainment facilities. In addition, RPXV has 
also shown to be highly transmissible between infected and naïve cohorts within the same animal   
room [14], a phenomenon that may further confound results of antiviral evaluation studies. These factors 
alone may have limited the use of this model for screening large numbers of potential antiviral 
compounds. The aerosol RPX model also requires a low infectious dose (estimated at 1 PFU) [9] 
remarkably close to the estimated lethal dose (approximately 20 PFU) [17] (Table 1). Viruses 2010, 2                  
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Figure 3. Lung pathology
1 of aerosolized RPX in rabbits. 
 
1 Lung histologic sections from naïve animals exposed to aerosolized RPXV that died on day +7 PI. 
(A) alveolar edema and necrosis of adjacent bronchiole (arrow) 50×; (B) diffuse alveolar edema 
with residual trapped air (200×); (C) severe hemorrhage adjacent to a necrotic airway (50×); (D) 
severe congestion of capillaries and venules with microhemorrhage (200×); (E) perivascular 
inflammation (50×); and (F) bronchiolar epithelial necrosis (200×).  
 
The narrow range between these two reported values (ID50 and LD50) makes it exceedingly difficult 
to use the model to study morbidity without causing death in RPXV-exposed animals. Increasing the 
dose of RPXV by aerosol (however slightly) has shown to significantly increase severity of disease 
and accelerate time to death, which may not be ideal for antiviral evaluation studies targeting reduction 
of morbidity rather than death as the primary endpoint. The low aerosol dose is in contrast to the ID 
inoculation model which requires between 500 and 1,000 PFU administered as a bilateral injection to 
ensure 100% lethality in nine week old rabbits [14].  
The narrow dose range of RPXV dose established in prior studies for the ID50 and the LD50 can be 
potentially problematic when using aerosol as the modality of exposure because of the inability to fine 
tune the model to produce only disease without lethality. Aerosol exposure is inherently variable 
especially when using larger animals that are exposed singly, as is the case with rabbits and nonhuman 
primates [30]. The reasons that aerosol viral infection dose may be variable, which are not limited to Viruses 2010, 2                  
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RPXV exposures, is primarily due to: (1) the uncontrollability of animal respiration during exposure 
and (2) fluctuating viral stability when in aerosol form during the experimental infection [31]. Because 
limited or no control can be exerted over these factors during individual exposure, the targeted 
exposure dose normally fluctuates up to 15–20% between animal cohorts. The variability experienced 
with this modality of exposure may limit the range of preferred biological response (infection with 
recovery  vs. lethality) when designing a study using the aerosol RPX model. A highly variable 
experimental aerosol dose may lead to an undesirable outcome by causing an overwhelming infection 
in some animals thereby negating or muting any potential therapeutic effects of an antiviral   
undergoing evaluation.  
The aerosol RPX model has been used sparingly for antiviral agent evaluation. Recent efforts have 
included assessment of a novel antiviral and efficacy of a new generation smallpox vaccine [17–18]. 
Although the use of the aerosol RPX model has been somewhat limited in the last 50 years, it has 
shown to be a reliable and rigorous test system considering the relative variety of chemical and 
biologic materials that have been evaluated (Table 2). The value of the aerosol RPX model was noted 
in the early 1960s when it’s utility was demonstrated in a passive hyperimmune sera-based therapeutic 
study [7]. In this study, rabbits were experimentally infected with dry powder formulation of RPV 
reported as measuring approximately 1.0 m in diameter at an estimated dose of ≈175 PFU. 
Thereafter, animals were administered hyperimmune sera derived and purified from convalescent 
rabbits from a previous study. Animals were intravenously administered with the hyperimmune sera at 
full strength or 1:10 or 1:100 dilutions immediately or three days postexposure. Results showed 
complete protection from death in the earliest treated groups treated with undiluted sera, whereas 
animals receiving dilutions in the early treatment group or the delayed treatment group showed signs 
of infection and only partial protection from death from RPX infection. This early study showed the 
relative severity of the model and acute action of the virus to infect and replicate in a range of tissues 
before a treatment can be administered.  
Early studies into the antiviral potential of orally-administered thiosemicarbazone compounds   
(3-methylisothiazole-5-carboxaldehyde thiosemicarbazone) have also been evaluated using the aerosol 
RPX model, although the route of the experimental infection was not specifically noted in this   
work [32]. Rabbits administered either 100 or 200 mg/kg daily for four days postexposure were 
partially protected from lethal RPX infection, and this agent failed to fully protect in additional testing 
using other orthopoxviral disease models. The relatively weak antiviral potential of thiosemicarbazone 
compounds (isatin--thiosemicarbazone) was confirmed in follow-up studies using a cowpox virus 
(CV) model [33] and was subsequently discounted as an effective antiviral against poxviruses. 
The development of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (cidofovir, HPMPC) 
as an antiviral for poxviruses has received attention in the last two decades due to its remarkable 
potency and relatively long intracellular half life [34]. Originally developed for use against CMV 
retinitis in AIDS patients and administered by intravenous infusion, cidofovir is a DNA polymerase 
inhibitor that can be highly specific to poxviruses [35]. Cidofovir effectively inhibits poxviruses in a 
number of systemic and lethal animal models and has been catalogued in reviews dedicated to the 
subject [25,27,35]. Cidofovir, surprisingly, has not been extensively tested using the aerosol RPX 
model. Recent work within our laboratories using the aerosol RPX model has shown IV-administered 
cidofovir to completely protect against infection and lethality when administered immediately after Viruses 2010, 2                  
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aerosol infection (Table 2) at a relatively low dose (10 mg/kg/day). Lower doses (1 and 0.1 mg/kg) 
given on the same schedule (daily for three days PI) resulted in only partial protection and 
development of disease. A reformulated version of cidofovir optimized for administration by 
inhalation is also being tested using this model [19].  
Table 2. Compounds and biologics evaluated using lethal aerosol RPX infection model. 
RPXV dose 
(reported) 
strain/(PFU/animal) 
(dose range) 
Test compound 
Effective treatment regimen 
Reference
Complete protection 
from lethality and 
infection 
Partial protection 
from death 
Utrecht/175 
(146–175) 
purified 
hyperimmune sera 
10 mL; 1:10, 1:100 
dilution/1day PI or 
10 mL/3 days after PI 
10 mL/1:10 dilution/3 
days PI 
[7] 
Utrecht/– 
thiosemicarbazone 
(M&B 7714) 
– 
100 or 200 mg/kg daily 
for 4 days 
[32] 
Utrecht/2,860 
(1,140–5,000) 
ST-246 (tecovirimat) 
40 mg/kg daily for 14 
days initiating 
immediately (0 h PI) 
40 mg/kg daily for 14 
days initiating +24, 
+48 or +72 h PI 
[19] 
Utrecht/296 
(96–468) 
cidofovir (vistide) 
10 mg/kg daily for 3 
days initiating either 
immediately or +24 h 
PI 
1 mg/kg daily for 3 
days initiating either 
immediately or +24 h 
PI 
[17] 
 
A relatively newly discovered small molecule denoted ST-246, targets a major gene product that 
encodes a major envelope protein (p37) required for production of extracellular virus [36]. This novel 
mechanism of action has resulted in ST-246 showing inhibitory effects against a number of 
orthopoxvirus in vitro [36]. ST-246 is also orally bioavailable, simplifying administration compared to 
other drugs that require intravenous infusion such as cidofovir. The aerosol RPX model was used to 
test the protection afforded by administration of ST-246 in a therapeutic evaluation study. Animals 
were exposed to aerosolized RPXV and then received ST-246 orally at 40 mg/kg/day, for 14 days, 
initiating immediately, or up to four days postexposure. Results showed that groups initiating treatment 
immediately postexposure were completely protected from RPXV infection and death, whereas 
animals in the delayed administration groups (1, 2, and 3 days PI) showed signs of infection and 
reduced survival. Clinical signs in animals partially protected by ST-246 were remarkably similar to 
what has been observed in cidofovir treated rabbits exposed to aerosolized RPX. Delay of initiation of 
treatment with ST-246 was the most important factor in the treatment of RPX disease in this   
study [17]. This evaluation study highlighted the usefulness of this model system and provided 
essential bridging data that has since produced evaluation nonhuman primate studies with monkeypox 
virus and VARV [37,38] although the modality of exposure in these studies was intravenous injection.  
4. Relevance of the RPXV Aerosol Model to the Biological Threat 
Smallpox is a disease considered to be transmitted via airborne transfer of VARV in natural 
communicable infections; the virus has adapted to transmit between human hosts via respiratory Viruses 2010, 2                  
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secretions for millennia. Although eradicated through vaccination for over four decades, the threat of a 
bioterrorism-type attack with VARV remains. Because clinical populations are nonexistent, reliance 
upon poxviral disease models are a critical and scrutinized portion of screening potential therapeutics. 
Models that emulate the similarities in terms of what is predicted from expected modality of exposure 
(e.g., inhalation) are therefore increasingly relevant for evaluation of antiviral compounds. The aerosol 
model of RPX represents such a model system. The aerosol RPX virus model is one of the more severe 
poxvirus animal models available for use in the evaluation of antiviral compounds [27], although the 
modality of experimental infection is technically challenging, and the dose required to achieve lethality 
exceedingly low when compared to other experimental routes of infection. Respiratory system 
involvement early after experimental infection is prominent in this model; targeting of the lung can be 
a desirable attribute for antiviral evaluation against a disease thought to be contracted by the airborne 
route. The use of the RPX aerosol model in antiviral testing has been sparse thus far; this is probably 
due more to logistical and husbandry restraints than the desire to utilize the model [27]. The aerosol 
RPX model, however, should not be overlooked as an ideal intermediate test system for antiviral 
testing that should be considered once available rodent models have been exhausted and prior to the 
use of larger species for testing such as monkeypox infection in nonhuman primates.  
Acknowledgements 
The authors wish to thank Peter J. Didier for careful preparation of the representative pathology 
figures provided in this manuscript. 
References and Notes 
1.  Wallin, A.; Luksiene, Z.; Zagminas, K.; Surkiene, G. Public health and bioterrorism: Renewed 
threat of anthrax and smallpox. Medicina (Kaunas) 2007, 43, 278–284. 
2.  Jansen, J. Experimenteel onderzoek van Kon-ijnensterfte door een filteebaar virus.  Tijdschr. 
Diergeneesk. 1942, 69, 505–514. 
3.  Greene, H.S.N. A pandemic of rabbit-pox. Proc. Soc. Exp. Biol. Med. 1933, 30, 892–894. 
4.  Greene, D.R. Rabbit pox II. Pathology of the epidemic disease. J. Exp. Med. 1934, 60, 441–455. 
5.  Li, G.; Chen, N.; Roper, R.L.; Feng. Z.; Hunter, A.; Danila, M.; Lefkowitz, E.J.; Buller, R.M.; 
Upton, C. Complete coding sequences of the rabbitpox virus genome. J. Gen. Virol. 2005, 86, 
2969–2977. 
6.  Rondle, C.J.; Dumbell, K.R. A poxvirus antigen associated with pathogenicity for rabbits. J. Hyg. 
1982, 89, 383–388. 
7.  Boulter, E.A. Value of serotherapy in a virus disease (rabbit pox). Lancet 1961, 2, 1012–1015. 
8.  Boulter, E.A. Protection against poxviruses. Proc. R. Soc. Med. 1969, 62, 295–297. 
9.  Westwood, J.C.; Boulter, E.A.; Bowen, E.T.; Maber, H.B. Experimental respiratory infection with 
poxviruses. I. Clinical virological and epidemiological studies. Brit. J. Exp. Pathol. 1966, 47, 
453–465. 
10.  Lancaster, M.C.; Boulter, E.A.; Westwood, J.C.; Randles, J. Experimental respiratory infection 
with poxviruses. II. Pathological studies. Brit. J. Exp. Pathol. 1966, 47, 466–471. Viruses 2010, 2                  
 
 
2106
11.  Bedson, H.S.; Duckworth, M.J. Rabbit pox: An experimental study of the pathways of infection in 
rabbits. J. Pathol. Bacteriol. 1963, 85, 1–20. 
12. Ali, A.N.; Turner, P.C.; Brooks, M.A.; Moyer, R.W. The SPI-1 gene of rabbitpox virus 
determines host range and is required for hemorrhagic pock formation.  Virology  1994,  202,  
305–314. 
13.  Moyer, R.W.; Rothe, C.T. The white pock mutants of rabbit poxvirus. I. Spontaneous host range 
mutants contain deletions. Virology 1980, 102, 119–132. 
14.  Adams, M.M.; Rice, A.D.; Moyer, R.W. Rabbitpox virus and vaccinia virus infection of rabbits as 
a model for human smallpox. J. Virol. 2007, 81, 11084–11095. 
15.  Brown, C.K.; Bloom, D.C.; Moyer, R.W. The nature of naturally occurring mutations in the 
hemagglutinin gene of vaccinia virus and the sequence of immediately adjacent genes. Virus 
Genes 1991, 5, 235–242. 
16.  Roy, C.J. Rabbitpox: An Aerosol Model for the Study of Aerosolized Poxviruses. J. Antivir. Res. 
2004, 43, S34. 
17. Nalca, A.; Hatkin, J.M.; Garza, N.L.; Nichols, D.K.; Norris, S.W.; Hruby, D.E.; Jordan, R. 
Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an 
aerosolized rabbitpox rabbit model. Antivir. Res. 2008, 79, 121–127. 
18.  Garza, N.L.; Hatkin, J.M.; Livingston, V.; Nichols, D.K.; Chaplin, P.J.; Volkmann, A.; Fisher, D.; 
Nalca, A. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against 
aerosolized rabbitpox virus in a rabbit model. Vaccine 2009, 27, 5496–5504. 
19.  Roy, C.J. Tulane University, New Orleans, LA, USA. Unpublished work, 2010. 
20.  Thomas, G. Sampling rabbit pox aerosols of natural origin. J. Hyg. (Lond.) 1970, 68, 511–517. 
21.  Dahlback, M.; Wollmer, P.; Jonson, B. Selective deposition of inhaled aerosols to mechanically 
ventilated rabbits. J. Aerosol. Med. 1994, 7, 315–324. 
22.  Roy, C.J.; Nichols, D.K. Pathology of aerosolized rabbitpox virus infection in rabbits. Vet. Pathol. 
2006, 43, 831. 
23.  De Clercq, E.; Neyts, J. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus 
infections. Rev. Med. Virol. 2004, 14, 289–300. 
24. De Clercq, E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus 
infections. Clin. Microbiol. Rev. 2001, 14, 382–397. 
25.  De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antivir. Res. 2002, 55, 1–13. 
26.  Neyts, J.; De Clercq, E. Therapy and short-term prophylaxis of poxvirus infections: Historical 
background and perspectives. Antivir. Res. 2003, 57, 25–33. 
27. Smee, D.F.; Sidwell, R.W. A review of compounds exhibiting anti-orthopoxvirus activity in 
animal models. Antivir. Res. 2003, 57, 41–52. 
28. Boyle, D.B. Quantitative assessment of poxvirus promoters in fowlpox and vaccinia virus 
recombinants. Virus Genes 1992, 6, 281–290. 
29. Kern,  E.R.  In vitro activity of potential anti-poxvirus agents. Antivir. Res. 2003, 57, 35–40. 
30. Hartings, J.M.; Roy, C.J. The automated bioaerosol exposure system: preclinical platform 
development and a respiratory dosimetry application with nonhuman primates.  J. Pharmacol. 
Toxicol. Method. 2004, 49, 39–55. Viruses 2010, 2                  
 
 
2107
31.  Roy, C.J.; Pitt, L.M.L. Infectious disease aerobiology: Aerosol challenge methods. In Biodefense: 
Research Methodology and Animal Models; Swearengen, J.L., Ed.; CRC Press: Boca Raton, FL, 
USA, 2005; Chapter 5, pp. 61–76. 
32.  Rao, A.R.; McFadzean, J.A.; Squires, S. The laboratory and clinical assessment of an isothiazole 
thiosemicarbazone (M 2 b 7714) against pox viruses. Ann. N. Y. Acad. Sci. 1965, 130, 118–127. 
33. Quenelle, D.C.; Keith, K.A.; Kern, E.R. In vitro and in vivo evaluation of isatin-beta-
thiosemicarbazone and marboran against vaccinia and cowpox virus infections.  Antivir. Res. 
2006, 71, 24–30. 
34.  De Clercq, E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends 
Pharmacol. Sci. 2002, 23, 456–458. 
35.  Bray, M.; Roy, C.J. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 2004, 54, 1–5. 
36.  Yang, G.; Pevear, D.C.; Davies, M.H.; Collett, M.S.; Bailey, T.; Rippen, S.; Barone, L.; Burns, 
C.; Rhodes, G.; Tohan, S.; Huggins, J.W.; Baker, R.O.; Buller, R.L.M.; Touchette, E.; Waller, K.; 
Schriewer, J.; Neyts, J.; DeClercq, E.; Jones, K.; Hruby, D.; Jordan, R. An orally bioavailable 
antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from 
lethal orthopoxvirus Challenge. J. Virol. 2005, 79, 13139–13149. 
37. Jordan, R.; Goff, A.; Frimm, A.; Corrado, M.L.; Hensley, L.E.; Byrd, C.M.; Mucker, E.; 
Shamblin, J.; Bolken, T.C.; Wlazlowski, C.; Johnson, W.; Chapman, J.; Twenhafel, N.; 
Tyavanagimatt, S.; Amantana, A.; Chinsangaram, J.; Hruby, D.E.; Huggins, J. ST-246 antiviral 
efficacy in a nonhuman primate monkeypox model: Determination of the minimal effective dose 
and human dose justification. Antimicrob. Agents Chemother. 2009, 53, 1817–1822. 
38. Huggins, J.; Goff, A.; Hensley, L.; Mucker, E.; Shamblin, J.; Wlazlowski, C.; Johnson, W.; 
Chapman, J.; Larsen, T.; Twenhafel, N.; Karem, K.; Damon, I.K.; Byrd, C.M.; Bolken, T.C.; 
Jordan, R.; Hruby, D. Nonhuman primates are protected from smallpox virus or monkeypox virus 
challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 2009, 53, 2620–2625. 
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 